Microcap Biotech GeoVax Labs

Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 3,030,304 shares of common stock at a purchase price of $1.65 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at a premium to market under Nasdaq rules. In a concurrent private placement, GeoVax has also agreed to issue and sell to the investor 9,090,910 shares of common stock (or common stock equivalents) at the same purchase price as in the registered direct offering.  In addition, the Company has agreed to issue to the investor in the offerings unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 12,121,214 shares of common stock.  The aggregate gross proceeds to the Company of both offerings are expected to be approximately $20 million.  The offerings are expected to close on or about May 27, 2022, subject to the satisfaction of customary closing conditions.  

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.

The unregistered investment options will be exercisable immediately upon issuance at an exercise price of $1.65 per share and will expire five years from the date of issuance for the investment options to be issued in the registered direct offering and six years from the date of issuance for the investment options to be issued in the private placement.

The shares of common stock, pre-funded warrants and shares of common stock underlying the pre-funded warrants (but excluding the shares of common stock and pre-funded warrants in the private placement and the investment options and the shares of common stock underlying the investment options) are being offered and sold by GeoVax pursuant to a “shelf” registration statement on Form S-3 (333-252437), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on January 26, 2021 and declared effective by the SEC on February 3, 2021.  The offering of the shares of common stock and the pre-funded warrants to be issued in the registered direct offering are being made only by means of a prospectus supplement that forms a part of the registration statement.  A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available at the SEC’s website located at http://www.sec.gov.  Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York,

he unregistered shares of common stock, pre-funded warrants and investment options described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants and investment options, have not been registered under the Act or applicable state securities laws.  Accordingly, the shares, the pre-funded warrants, the investment options and the shares of common stock underlying the pre-funded warrants and investment options may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to an accredited investor. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered shares of common stock and the shares issuable upon exercise of the unregistered pre-funded warrants and investment options.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  

nur ein tag spaeter tritt ein,wovor ich gestern schon gewarnt habe,aber jetzt wird die Aktie durchaus mal interessant,immerhin ein covid impfstoff dabei und wieder genug kohle am start (bis zum naechsten offering),zur krebspipeline kann ich nix sagen,ich setze da voll auf Sellas life sciences (SLS) mit sagenhaften klinischen Erfolgen bisher und kaum teurer als Geovax,mal sehen .......  

 

schaust wo ich angefangen hab zu posten, da lagen wir noch unter 1$ also alles gut. Der Kurs wird sowieso nicht hier gemacht, pushen bringt hier nichts.  

hatte ich meinen Teilverkauf zu 2,25€ ja mitgeteilt. Also man konnte hier schon Geld verdienen bei 300 Prozent Performance im Hoch.  

wieder nach dem Offering. Kurrzeitig gings sogar wieder über 2$.  

Erholung im Gange  

mir gestern wieder paar Stück ins Nest gelegt. Shortquote ist weiter am steigen, soll jetzt über 20 Prozent betragen und der Laden ist mit ca. 35 Millionen Cash erstmal durchfinanziert.  

halloechen nochmal,

ihr wollt auf der "Affenpockenwelle" mitsurfen ? Dann versucht es am besten mal mit der hier:

SIGA Technologies, Inc. (SIGA)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Quote Lookup

13.40+3.76 (+39.00%)
As of 02:56PM EDT. Market open.  

damit gerechnet, dass der Kurs nach dem Offering zu 1,65$ einbricht. Dem ist aber nicht so. Nur einen Tag später gings wieder über 2$ bevor sogar die Kapitalerhöhung abgeschlossen wurde.  

folgendes zurm Thema Affenpocken gepostet.

https://www.linkedin.com/feed/update/activity:6936007129799553024  

zu haben, in US Börse zu, Schlusskurs 2,01, hier für teilweise unter 1,70€ zu haben.  

https://twitter.com/Geovax_News/status/...qDZVq1PajIY0AsjdMA&s=19  

aus unter einem Dollar. Wie man sieht sehr risky, deshalb keine Kaufempfehlung. Dafür müsst ihr schon euren Anlageberater bei der Bank kontaktieren.  

...  

oder diesmal mit Fundament und nachhlatig? Meinungen`?  

http://stocktwits.com/Georgie128/message/473800440  

Sehr schön, weiter geht's. Mal schauen was es dann aus dem Treffen im WH zu lesen gibt.  

wenn jetzt noch ne gute News kommen würde ;-)
 

aufgegangen. Top Aktie.  

https://www.globenewswire.com/news-release/2022/...-Immunization.html


 

Läuft unverändert weiter.  

und diesmal ist die Wahscheinlichkeit eines Offerings, welches das Momentum zerstört, äußerst gering. Deswegen bleib ich mit einer Position weiterhin dabei, denn der große Run könnte noch bevorstehen. Desweiteren hab ich noch Tonix und Aethlon Medical als Affenplays im Depot. Tonix ist auch schon 50% vom Tief gelaufen, Aethlon aber noch ziemlich unverändert, obwohl auch hier bis zu 10 Millionen Aktien am Tag gehandelt wurden letztens. Viel Erfolg.  

holy moly

o_O

https://finance.yahoo.com/quote/...LffhrTA7ev8AexUVcBOHKDZBW4S8koaLoO  

Kurz Luft geholt und nun hoffentlich in Richtung 3,5$